141 related articles for article (PubMed ID: 8503421)
1. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.
Gupta BK; Spinowitz BS; Charytan C; Wahl SJ
Am J Kidney Dis; 1993 Jun; 21(6):659-62. PubMed ID: 8503421
[TBL] [Abstract][Full Text] [Related]
2. Atheroembolic disease following administration of tissue plasminogen activator (TPA).
Aggarwal K; Tjahja IE
Clin Cardiol; 1996 Nov; 19(11):906-8. PubMed ID: 8914787
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol embolization syndrome following thrombolytic therapy with streptokinase and tissue plasminogen activator.
Ben-Chitrit S; Korzets Z; Hershkovitz R; Bernheim J; Schneider M; Bernheim J
Nephrol Dial Transplant; 1994; 9(4):428-30. PubMed ID: 8084460
[No Abstract] [Full Text] [Related]
4. Development of cholesterol embolization syndrome after intravenous streptokinase for acute myocardial infarction.
Queen M; Biem HJ; Moe GW; Sugar L
Am J Cardiol; 1990 Apr; 65(15):1042-3. PubMed ID: 2327344
[No Abstract] [Full Text] [Related]
5. [Cholesterol crystal embolisms due to systemic thrombolysis of an acute myocardial infarct].
Diethelm A; Vorburger C; Anabitarte M; Haag E
Schweiz Med Wochenschr; 1994 Aug; 124(33):1437-41. PubMed ID: 7939511
[TBL] [Abstract][Full Text] [Related]
6. Purple toes syndrome following stroke thrombolysis and warfarin therapy.
Mooney T; Joseph P
Intern Med J; 2014 Jan; 44(1):107-8. PubMed ID: 24450530
[No Abstract] [Full Text] [Related]
7. Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction.
Massel D; Gill JB; Cairns JA
Can J Cardiol; 1991 Sep; 7(7):298-302. PubMed ID: 1933636
[TBL] [Abstract][Full Text] [Related]
8. Embolic cerebral infarction and gastrointestinal hemorrhage following thrombolytic therapy for acute myocardial infarction.
Chang MC; Lee AY; Chang WF; Chen TJ
Echocardiography; 2002 Feb; 19(2):139-41. PubMed ID: 11926976
[TBL] [Abstract][Full Text] [Related]
9. A case of intraocular haemorrhage secondary to thrombolytic therapy.
Berry C; Weir C; Hammer H
Acta Ophthalmol Scand; 2002 Oct; 80(5):561-2. PubMed ID: 12390175
[No Abstract] [Full Text] [Related]
10. [Pulmonary hemorrhage and acute respiratory failure secondary to thrombolytic treatment with tissue plasminogen activator (rt-PA) in patients with acute myocardial infarction].
Sandar Núñez D; Ruiz Santana S; García Jiménez A; Castro Mao M
Med Clin (Barc); 1997 Mar; 108(8):318. PubMed ID: 9121219
[No Abstract] [Full Text] [Related]
11. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
[TBL] [Abstract][Full Text] [Related]
12. Myocardial Infarction Following Intravenous Thrombolysis for Acute Ischemic Stroke: Case Report and Literature Review.
Mannino M; Asciutto S; Terruso V; Gammino M; Cellura MG; Monaco S
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e105-e107. PubMed ID: 28434774
[TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator and cholesterol crystal embolization.
Bhardwaj M; Goldweit R; Erlebacher J; Kashani M; Levin D; Leber G
Ann Intern Med; 1989 Oct; 111(8):687-8. PubMed ID: 2508531
[No Abstract] [Full Text] [Related]
14. [Usefulness and safety of intravenous thrombolytic therapy for elderly patients with acute myocardial infarction: relationship with cardiac rupture].
Sakai M; Imai T; Kuboki K; Maeda S; Ueda S; Kuwajima I; Ohkawa S; Matsushita S
J Cardiol; 1999 Mar; 33(3):153-61. PubMed ID: 10225195
[TBL] [Abstract][Full Text] [Related]
15. Acute myocardial infarction and thrombolytic therapy.
Yasuda T; Gold HK
Thromb Res Suppl; 1990; 10():73-9. PubMed ID: 2107600
[No Abstract] [Full Text] [Related]
16. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
Cannas S; De Leo A; Marzari A
G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
[TBL] [Abstract][Full Text] [Related]
17. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous arterial embolization after thrombolytic therapy for acute myocardial infarction: the role of transesophageal echocardiography.
Karalis DG; Kaulback KW; Ross JJ; Uricchio FJ; Chandrasekaran K
Cathet Cardiovasc Diagn; 1994 Mar; 31(3):199-201. PubMed ID: 8025936
[TBL] [Abstract][Full Text] [Related]
19. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J
Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013
[TBL] [Abstract][Full Text] [Related]
20. Retro-orbital hemorrhage after thrombolysis for acute myocardial infarction.
Cunneen TS; Morlet N
N Engl J Med; 2007 Oct; 357(14):1448-9. PubMed ID: 17914052
[No Abstract] [Full Text] [Related]
[Next] [New Search]
